Low high-density lipoprotein cholesterol as the possible risk factor for stroke

Acta Clinica Croatica

Volumn 49, Issue 4, 2010, Pages 429-439

  Demarin, Vida ^a,b   Lisak, Marijana ^a,b   Morović, Sandra ^a,b   Cengić, Tomislav ^a,b  

^a University Department of Neurology   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Atherosclerosis diagnosis; Atherosclerosis pathology; Atherosclerosis therapy; Brain infarction blood; Brain infarction diagnosis; Brain infarction risk factors; Cholesterol; Cholesterol blood; HDL metabolism

Indexed keywords

ATORVASTATIN; EZETIMIBE; FATTY ACID; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OLEIC ACID; PLACEBO; TRIACYLGLYCEROL;

AEROBIC EXERCISE; ATHEROSCLEROSIS; BLOOD PRESSURE; BRAIN INFARCTION; CACAO; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONGESTIVE CARDIOMYOPATHY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; ENERGY EXPENDITURE; FOOD INTAKE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; NONHUMAN; PHYSICAL ACTIVITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; NON INSULIN DEPENDENT DIABETES MELLITUS;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HUMANS; LIPIDS; METABOLIC SYNDROME X; RISK FACTORS; STROKE;

EID: 80052821475     PISSN: 03539466     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Rizzo M, Corrado E, Coppola G, Muratori I, Novo G, Novo S. Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol. Atherosclerosis 2008;200:389-95.
2. Rubins BH, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, Robins SJ; VA-HIT Study Group. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001;103:2828-33.
3. Robins S, Collins D, Nelson JN, Bloomfield HE, Asztalos BF. Cardiovascular events with increased lipoprotein-associated phospholipase A2 and low high-density lipoprotein cholesterol. The Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2008;28:1172-8.
4. Russman AN, Schultz LR, Zaman IF, Rehman MF, Silver B, Mitsias P, Nerenz DR. A signicant temporal and quantitative relationship exists between highdensity lipoprotein levels and acute ischemic stroke presentation. J Neurol Sci 2009;279:53-6.
5. Uddin M, Alam B, Jabbar MA, Mohammad QD, Ahmed S. Association of lipid profile with ischemic stroke. Mymensingh Med J 2009;18:131-5.
6. Lindenstrom E, et al. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 1994;309:11-5.
7. Tanne D, et al. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997;28:83-7.
8. Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly. The Northern Manhattan Stroke Study. JAMA 2001;285:2729-35.
9. Leppälä JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Pressure, cholesterol, and antioxidants. Different risk factors for different stroke subtypes. Association of blood pressure, cholesterol, and antioxidants. Stroke 1999;30:2535-40.
10. Tirschwell DL, et al. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004;63:1868-75.
11. Wannamethee SG, Gerald Shaper AG, Ebra-him S. HDL-cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke 2000;31:1882-8.
12. Amarenco P, Goldstein LB, Callahan A, Sillesend H, Hennerici MG, O'Neill BJ, Rudolph AE, Simunovic L, Zivinh JA, Welch KMA on behalf of the SP ARCL Investigators. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SP ARCL) trial. Atherosclerosis 2009;204:515-20.
13. Amarenco P, Goldstein LB, Messig M, O'Neil BJ, Callahan A, Sillesen H, Hennerici MG, Zivinh JA, Welch KMA, on behalf of the SP ARCL Investigators. Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke 2009;40:2486-92.
14. Asumi M, Yamaguchi T, Saitob K, Kodamab S, Miyazawaa H, Matsui H, Suzuki E, Fukudad H, Soneb H. Are serum cholesterol levels associated with silent brain infarcts? The Seiryo Clinic Study. Atherosclerosis 2010; 210(2):674-7 (article in press).
15. Graban A, Bednarska-Makaruk M, Bochyńska A, Lipczyńska-Łojkowska W, Ryglewicz D, Wehr H. Vascular and biochemical risk factors of vascular dementia after lacunar strokes (S-VaD) and after multi-infarcts in strategic areas (M-VaD). J Neurol Sci 2009;283:116-8.
16. Yokokawa H, Goto A, Terui K, Funami Y, Wa-tanabe K, Yasumura S. Prevalence of metabolic syndrome and serum marker levels in patients with four subtypes of cerebral infarction in Japan. J Clin Neurosci 2008;15:769-73.
17. Menotti A, Lanti M, Zanchetti A, Botta G, Laurenzi M, Terradura-Vagnarelli O, Mancini M. The role of HDL cholesterol in metabolic syndrome predicting cardiovascular events. The Gubbio population study. Nutr Metab Cardiovasc Dis 2009;xx:1-8. Article in press.
18. Gardener H, Della Morte D, Elkind MSV, Sacco RL, Rundek T. Lipids and carotid plaque in the Northern Manhattan Study (NO MAS). BMC Cardiovasc Disord 2009;9:55.
19. Wang S, Sun Z, Ruan W, Guo Y, Wang Y, Jin H, Yuan, Wei Q. Dyslipidaemia among diabetic patients with ischemic stroke in a Chinese hospital. Chin Med J 2009;122:2567-72.
20. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25.
21. Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, Saely CH. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 2005;28:108-14.
22. Frost G, Leeds AA, Doré CJ, Madeiros S, Brading S, Dornhorst A. Glycaemic index as a determinant of serum HDL-cholesterol concentration. Lancet 1999;353:1045-8.
23. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 2008;14(Suppl):S1-S28.
24. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intimamedia thickness. N Engl J Med 2009;361:2113-22.
25. Faleautori. Can chocolate lower your risk of stroke? American Academy of Neurology's 62nd Annual Meeting, Toronto, April 10-17, 2010.
26. Ding EL, Hutfless SM, Ding X, Girotra S. Chocolate and prevention of cardiovascular disease: a systematic review. Nutr Metab2006;3:2.
27. Poli A, Marangoni F, Paoletti R, Mannarino E, Lupattelli G, Notarbartolo A, Aureli P, Bernini F, Cicero A, Gaddi A, Catapano A, Cricelli C, Gattone M, Marrocco W, Porrini M, Stella R, Vanotti A, Volpe M, Volpe R, Cannella C, Pinto A, Del Toma E, La Vecchia C, Tavani A, Manzato E, Riccardi G, Sirtori C, Zambon A. Consensus document. Nonpharmacological control of plasma cholesterol levels. Nutr Metab Cardiovasc Dis 2008;18:S1-S16.
28. Sesso HD. Alcohol and cardiovascular health: recent findings. Am J Cardiovasc Drugs 2001;1:167-72.
29. Davies MJ, Baer DJ, Judd JT, Brown ED, Campbell WS, Taylor PR. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. JAMA 2002;287:2559-62.
30. Beulens JW, Rimm E, Ascherio A, Spiegelman D, Hendriks HFJ, Mukamal KJ. Alcohol consumption and risk for coronary heart disease among men with hypertension. Ann Int Med 2007;146:10-9.
31. Schaefer EJ, Gleason JA, Dansinger ML. The effects of low-fat, high-carbohydrate diets on plasma lipoproteins, weight loss, and heart disease risk reduction. Curr Atheroscler Rep 2005;7:421-7.
32. Descovich GC, Ceredi C, Gaddi A, Benassi MS, Mannino G, Colombo L, et al. Multicentre study of soybean protein diet for outpatient hyper-cholesterolaemic patients. Lancet 1980;ii:709-12.
33. Zhan S, Ho SC. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr 2005;81:397-408.
34. Lichtenstein AH. Thematic review series: patient-oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns. J Lipid Res 2006;47:1661-7.
35. Gotto AM Jr. High-density lipoprotein cholesterol: an updated view. Curr Opin Pharmacol 2001;1:109-12.
36. Wilson PW F, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
37. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. AFCAPS /TexCAPS Research Group. JAMA 1998;279:1615-22.
38. Schroeder H. Protective mechanisms of the Mediterranean diet in obesity and type 2 diabetes. J Nutr Biochem 2007;18:149-60.
39. Kozarsky KF, Donahee MH, Glick JM, Krieger M, Rader DJ. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor deficient mouse. Arterioscler Thromb Vasc Biol 2000;20:721-7.
40. van Haperen R, van Tol A, Vermeulen P, Jauhiainen M, vangent T, van den Berg P, Ehnholm S, Grosveld F, van der Kamp A, de Crom R. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000;20:1082-8.
41. Rundek T, Demarin V. Carotid intima-media thickness (IMT): a surrogate marker of atherosclerosis. Acta Clin Croat 2006;45:45-51.
42. Demarin V, Lovrenčić-Huzjan A, Trkanjec Z, Vuković V, Šerić V, Vargek-Solter V, Lušić I, Kadojić D, Bielen I, Tuškan Mohar L, Aleksić-Shibabi A, Dikanović M, Hat J, DeSyo D, Lupret V, Beroš V. Recommendations for stroke management - update 2006. Acta Clin Croat 2006;45:219-85.